Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$4.99 +3.7%	$5.55	$4.71 ▼ $12.43	$695.61M	1.36	2.21 million shs	1.57 million shs
CMPS COMPASS Pathways	$8.38 -0.5%	$9.98	$5.01 ▼ $12.75	$519.06M	2.48	689,953 shs	369,848 shs
HRMY Harmony Biosciences	$29.40 +1.3%	$31.94	$18.61 ▼ $39.26	$1.67B	0.73	374,775 shs	385,764 shs
SUPN Supernus Pharmaceuticals	$29.40 +1.8%	$31.30	$21.99 ▼ $39.09	$1.61B	0.99	384,416 shs	361,633 shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	-2.04%	-5.31%	-7.14%	-39.88%	-56.39%
CMPS COMPASS Pathways	-1.29%	-8.28%	-11.65%	+4.86%	-13.91%
HRMY Harmony Biosciences	-0.55%	-7.13%	-10.21%	-8.31%	-11.95%
SUPN Supernus Pharmaceuticals	-0.45%	-9.78%	-17.87%	+4.34%	-22.43%

Tiny Biotech Stock Wins $75 Billion Patent (Ad)

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	0.8295 of 5 stars	3.4	1.0	0.0	1.8	0.0	0.6
CMPS COMPASS Pathways	2.0307 of 5 stars	3.5	2.0	0.0	2.3	3.3	0.0
HRMY Harmony Biosciences	4.1593 of 5 stars	3.3	0.0	0.0	3.4	4.2	4.4
SUPN Supernus Pharmaceuticals	3.8925 of 5 stars	3.5	1.0	4.1	2.1	0.8	1.9

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	2.75	Moderate Buy	$10.00	100.40% Upside
CMPS COMPASS Pathways	3.00	Buy	$47.40	465.63% Upside
HRMY Harmony Biosciences	2.50	Moderate Buy	$40.63	38.18% Upside
SUPN Supernus Pharmaceuticals	3.00	Buy	$41.00	39.46% Upside

Current Analyst Ratings

Latest AUPH, CMPS, HRMY, and SUPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/18/2024	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
4/12/2024	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$49.00
4/9/2024	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
4/1/2024	CMPS COMPASS Pathways	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$30.00
3/28/2024	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$49.00
3/1/2024	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
3/1/2024	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00
2/28/2024	SUPN Supernus Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $41.00
2/27/2024	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
2/23/2024	AUPH Aurinia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $10.00
2/23/2024	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$49.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$175.51M	4.11	N/A	N/A	$2.63 per share	1.90
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$3.65 per share	N/A
HRMY Harmony Biosciences	$582.02M	2.87	$2.63 per share	11.19	$7.97 per share	3.69
SUPN Supernus Pharmaceuticals	$607.52M	2.65	$1.61 per share	18.30	$16.87 per share	1.74

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	-$78.02M	-$0.54	N/A	9.07	N/A	-44.45%	-20.10%	-14.84%	5/2/2024 (Confirmed)
CMPS COMPASS Pathways	-$118.46M	-$2.39	N/A	N/A	N/A	N/A	-58.72%	-49.46%	5/9/2024 (Estimated)
HRMY Harmony Biosciences	$128.85M	$2.12	13.87	7.46	0.41	22.16%	27.49%	16.83%	4/30/2024 (Confirmed)
SUPN Supernus Pharmaceuticals	$1.32M	N/A	0.00	20.00	N/A	0.22%	0.14%	0.09%	5/14/2024 (Estimated)

Latest AUPH, CMPS, HRMY, and SUPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/2/2024	N/A	AUPH Aurinia Pharmaceuticals	-$0.17	N/A	+$0.17	N/A	N/A	N/A
4/30/2024	N/A	HRMY Harmony Biosciences	$0.64	N/A	-$0.64	N/A	N/A	N/A
2/29/2024	Q4 2023	CMPS COMPASS Pathways	-$0.37	-$0.53	-$0.16	-$0.53	N/A	N/A
2/27/2024	Q4 2023	SUPN Supernus Pharmaceuticals	$0.41	$0.02	-$0.39	$0.02	$155.03 million	$164.30 million
2/22/2024	Q4 2023	HRMY Harmony Biosciences	$0.74	$0.45	-$0.29	$0.45	$168.90 million	$168.40 million
2/15/2024	12/31/2023	AUPH Aurinia Pharmaceuticals	-$0.16	-$0.19	-$0.03	-$0.19	$45.00 million	$45.10 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.20	5.50	4.99
CMPS COMPASS Pathways	0.14	13.33	13.33
HRMY Harmony Biosciences	0.38	2.75	2.72
SUPN Supernus Pharmaceuticals	N/A	1.70	1.43

Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
CMPS COMPASS Pathways	46.19%
HRMY Harmony Biosciences	86.23%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	4.30%
CMPS COMPASS Pathways	23.99%
HRMY Harmony Biosciences	28.40%
SUPN Supernus Pharmaceuticals	8.76%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	144.62 million	138.40 million	Optionable
CMPS COMPASS Pathways	186	61.94 million	47.08 million	Optionable
HRMY Harmony Biosciences	246	56.79 million	40.66 million	Optionable
SUPN Supernus Pharmaceuticals	652	54.74 million	49.94 million	Optionable

AUPH, CMPS, HRMY, and SUPN Headlines

Source	Headline
	Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN) markets.businessinsider.com - April 15 at 11:22 AM
	Phocas Financial Corp. Sells 35,507 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) marketbeat.com - April 15 at 8:20 AM
	Supernus receives FDA rejection for Parkinson's treatment, submits additional data uk.investing.com - April 10 at 2:23 AM
	US FDA declines to approve Supernus' Parkinson's combination again (April 8) yahoo.com - April 9 at 4:12 PM
	Supernus Pharmaceuticals, Inc.: Supernus Provides Regulatory Update for SPN-830 finanznachrichten.de - April 8 at 1:44 PM
	FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease biospace.com - April 8 at 1:44 PM
	Supernus stock slides as FDA rejects Parkinson's disease infusion device msn.com - April 8 at 1:44 PM
	Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease finance.yahoo.com - April 8 at 1:44 PM
	Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down to $33.55 marketbeat.com - April 8 at 11:37 AM
	U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease reuters.com - April 8 at 8:44 AM
	Supernus Provides Regulatory Update for SPN-830 globenewswire.com - April 8 at 8:00 AM
	Assenagon Asset Management S.A. Buys New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) marketbeat.com - April 6 at 4:40 AM
	Padmanabh P. Bhatt Sells 14,491 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock insidertrades.com - March 26 at 4:32 AM
	Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Price Down 3.9% Following Insider Selling marketbeat.com - March 25 at 6:39 PM
	Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $511,677.21 in Stock marketbeat.com - March 25 at 6:24 PM
	Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 12,364 Shares insidertrades.com - March 22 at 9:58 AM
	Supernus Pharmaceuticals, Inc.: Supernus Announces Fourth Quarter and Full Year 2023 Financial Results finanznachrichten.de - March 21 at 3:57 AM
	Supernus Pharmaceuticals executive trades company stock investing.com - March 16 at 8:45 PM
	SUPN Apr 2024 29.000 call finance.yahoo.com - March 16 at 10:13 AM
	Padmanabh P. Bhatt Sells 3,884 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock insidertrades.com - March 16 at 6:32 AM
	Supernus Pharmaceuticals executive sells over $2.1m in stock investing.com - March 15 at 7:01 PM
	Supernus to Participate in Two Upcoming Investor Conferences globenewswire.com - March 6 at 4:30 PM
	Supernus Pharmaceuticals: Moving Through An 'Inflection Year' seekingalpha.com - March 4 at 11:41 AM
	Supernus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations finance.yahoo.com - February 29 at 7:35 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aurinia Pharmaceuticals

NASDAQ:AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

COMPASS Pathways

NASDAQ:CMPS

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Harmony Biosciences

NASDAQ:HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Supernus Pharmaceuticals

NASDAQ:SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial